TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26160875

Group type: EXPERIMENTAL
Intervention: Virtual-reality simulator training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional apprenticeship training
Number of subjects: 16
Study: 23325044

Group type: EXPERIMENTAL
Intervention: ICD programmed with a monitor zone for slow VTs at heart rates 130-186 b.p.m.
Number of subjects: 200
Study: 21982290

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 538
Study: 18496372

Group type: EXPERIMENTAL
Intervention: Intravenous alanyl‐glutamine supplementation (0.3 g/kg x day(‐1) from day 4 until day 17) and intravenous growth hormone (50 microg/kg x day(‐1) from day 10 onward)
Number of subjects: 30
Study: 16892433

Group type: EXPERIMENTAL
Intervention: AdVEGF121 (4 x 10(10) pu)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AdVEGF121 and Placebo
Number of subjects: 10
Study: 12929062

Group type: EXPERIMENTAL
Intervention: Bendable catheter
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Sphincterotome
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard catheter (when failed)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Further manoeuvres
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Needle-knife papillotomy
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Overall ERCP
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Pancreatitis
Number of subjects: 312
Study: 10920133

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF administered subcutaneously after chemotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: PEG‐rHuMGDF administered before chemotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: PEG‐rHuMGDF administered after chemotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF administered alone
Number of subjects: 68
Study: 8599991

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) substitution in 15/27 patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) substitution
Number of subjects: 27
Study: 1637696

Group type: EXPERIMENTAL
Intervention: narrowband (TL-01) phototherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: etretinate TL-01 combination therapy (re-TL-01)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: etretinate and PUVA (re-PUVA)
Number of subjects: 45
Study: 3931143

Group type: EXPERIMENTAL
Intervention: IV doses (0.2, 0.4, or 0.6 mg/kg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oral doses (2, 3, or 4 mg/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31755872

Group type: EXPERIMENTAL
Intervention: Mood monitoring using a mobile health system
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Signposting to stress management video
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Viewing of advisory videos
Number of subjects: 107
Study: 29409833

Group type: EXPERIMENTAL
Intervention: Algorithm for abortion intravenous sedation dosing (AAID)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 196
Study: 25780261

Group type: EXPERIMENTAL
Intervention: Unstable shoes worn for at least 36 hours/week for a month
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no unstable shoes)
Number of subjects: 20
Study: 26349796

Group type: EXPERIMENTAL
Intervention: Three-in-one injection comfort system (ICS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 10 percent lidocaine pump spray
Number of subjects: 58
Study: 23550945

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21039344

Group type: EXPERIMENTAL
Intervention: Vscan pocket device
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vivid i system
Number of subjects: 61
Study: 18595551

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16316482

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/d
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 14588157

Group type: EXPERIMENTAL
Intervention: Clinical Assessment (CA)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 182
Study: 11554235

Group type: EXPERIMENTAL
Intervention: Tropisetron (0.2 mg/kg/24 h intravenously)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Granisetron (40 micrograms/kg/24 h intravenously)
Number of subjects: 51
Study: 9692122

Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone dipropionate (BDP) 400 micrograms daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nasal anti-histamine levocabastine 200 micrograms daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (21 healthy children aged 5-15 years)
Number of subjects: 21
Study: 8155502

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus teicoplanin prophylaxis beginning before the onset of aplasia and fever (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ceftazidime plus teicoplanin prophylaxis beginning at the onset of fever (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus teicoplanin prophylaxis (both groups)
Number of subjects: 60
Study: 3168450

Group type: EXPERIMENTAL
Intervention: 100 mg Mifepristone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31850808

Group type: EXPERIMENTAL
Intervention: FMF patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 30075886

Group type: EXPERIMENTAL
Intervention: Carvacrol (1.2 mg/kg/day) for two months
Number of subjects: 20
Study: 28530702

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25449225

Group type: EXPERIMENTAL
Intervention: Heated humidified gas (HHG) at delivery and until neonatal unit arrival; humidifier set to 37°C
Number of subjects: 203

Group type: COMPARATOR
Intervention: Cold, dry gas
Number of subjects: 203
Study: 23839073

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with bougie
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope alone
Number of subjects: 20
Study: 21586416

Group type: EXPERIMENTAL
Intervention: Calorie restriction
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Calorie restriction with exercise
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study: 19543669

Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain management programme
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 307
Study: 16624147

Group type: EXPERIMENTAL
Intervention: nCPAP therapy in OSAHS group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: nCPAP therapy in OSAHS with CHD group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: COMPARATOR
Intervention: CHD group
Number of subjects: 80
Study: 15615551

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Open Repair (OR)
Number of subjects: 153
Study: 11382214

Group type: EXPERIMENTAL
Intervention: Pedagogic aid: a flow diagram of an RCT
Number of subjects: 0
Study: 9160949

Group type: EXPERIMENTAL
Intervention: Incision parallel to the superior cluneal nerves (study group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oblique incision (control group)
Number of subjects: 57
Study: 7711429

Group type: EXPERIMENTAL
Intervention: Ethanol sclerotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 70
Study: 30763292

Group type: COMPARATOR
Intervention: EHR-only model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EHR-plus model
Number of subjects: 100
Study: 29731620

Group type: EXPERIMENTAL
Intervention: Chronic Care (CCC) education program led by registered respiratory therapists
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Chronic Care (CCC) education program
Number of subjects: 308
Study: 27163518

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (VE) therapy, 0.5g promestriene cream twice a week for 6 weeks before surgery
Number of subjects: 186

Group type: COMPARATOR
Intervention: Non-vaginal estrogen (non-VE) therapy, no pharmacologic preparation before surgery
Number of subjects: 186
Study: 25252514

Group type: EXPERIMENTAL
Intervention: British Thoracic Society guidelines (Group I)
Number of subjects: 325

Group type: COMPARATOR
Intervention: American Thoracic Society guidelines (Group II)
Number of subjects: 325
Study: 22567139

Group type: EXPERIMENTAL
Intervention: Syrups of combination ART including Nevirapine, Zidovudine, Abacavir and Lamivudine
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Scored adult-dose tablets prescribed according to WHO weightband tables
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Syrups
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 1206
Study: 19673898

Group type: EXPERIMENTAL
Intervention: subcutaneous sumatriptan 6 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 18603748

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 36
Study: 16020594

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Non-invasive strategy
Number of subjects: 2457
Study: 12463857

Group type: EXPERIMENTAL
Intervention: Tailored Web‐based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-tailored Web‐based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-tailored paper-based intervention
Number of subjects: 0
Study: 10634671

Group type: EXPERIMENTAL
Intervention: Knee-extensor training for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 7589618

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 2066773

Group type: EXPERIMENTAL
Intervention: Temporal-parietal lesions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Parietal lesions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Frontal lesions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shock novels
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N2 component
Number of subjects: 36
Study: 6973990

Group type: EXPERIMENTAL
Intervention: Fluproquazone (200 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (1000 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31227028

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 or 50 mg/day for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29210202

Group type: EXPERIMENTAL
Intervention: High-intensity physical activity (>8 hours/week)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Total physical activity (measured in MET hours)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Low-intensity physical activity
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: High-intensity physical activity
Number of subjects: 422
Study: 27428202

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) monotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r) + 2 NRTIs
Number of subjects: 23
Study: 23838727

Group type: EXPERIMENTAL
Intervention: P-ESDM
Number of subjects: 49

Group type: COMPARATOR
Intervention: Community intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 22139387

Group type: EXPERIMENTAL
Intervention: Percutaneous screw fixation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Plate and screws fixation
Number of subjects: 90
Study: 20456070

Group type: EXPERIMENTAL
Intervention: Pain Provocation Technique (PPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard multimodal inpatient treatment
Number of subjects: 40
Study: 17276260

Group type: EXPERIMENTAL
Intervention: Aspherical Tecnis Z9000 IOL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spherical CeeOn Edge 911 IOL
Number of subjects: 20
Study: 16563249

Group type: EXPERIMENTAL
Intervention: DD genotype in male hypertensive patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: D allele in male EH group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SBP and PP in males with DD genotype
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SBP, DBP, and PP in female hypertensive patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Distribution ratio of DD genotype in male EH group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DBP in all three genotypes in male EH group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SBP, DBP, and PP between II and ID genotype in male EH group
Number of subjects: 100
Study: 12172688

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10460188

Group type: EXPERIMENTAL
Intervention: Sm‐153 PHYP/triamcinolone hexacetonide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corticosteroid alone (triamcinolone hexacetonide)
Number of subjects: 60
Study: 8552455

Group type: EXPERIMENTAL
Intervention: Curvature of the visible contour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual angle of the visible arc
Number of subjects: 0
Study: 2182423

Group type: EXPERIMENTAL
Intervention: Sequential decision strategy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Fixed sample size approach
Number of subjects: 161
Study: 91836

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention programme
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study: 30726268

Group type: EXPERIMENTAL
Intervention: Heated humidification mask
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-heated humidification mask (placebo)
Number of subjects: 37
Study: 29979445

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg over 10 minutes before anesthesia induction and then 0.5 μg/kg/h until peritoneal closure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 0
Study: 26803950

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A injections (BoNT-A) in the parotid glands only
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiotherapy (RT) on the parotid and posterior part of the submandibular glands
Number of subjects: 20
Study: 25078309

Group type: EXPERIMENTAL
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with ribavirin (group 1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks without ribavirin (group 2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks with ribavirin (group 3)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks without ribavirin (group 4)
Number of subjects: 168
Study: 22446502

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels >10% at 3 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels >1-10% at 3 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels ≤1% at 3 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with >35% Philadelphia chromosome-positive metaphases at 3 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with ≤35% Philadelphia chromosome-positive metaphases at 3 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels >1% at 6 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels ≤1% at 6 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with >0% Philadelphia chromosome-positive at 6 months
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with 0% Philadelphia chromosome-positive at 6 months
Number of subjects: 1303
Study: 20129016

Group type: EXPERIMENTAL
Intervention: C.E.R.A.
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Comparator ESA
Number of subjects: 2737
Study: 17657694

Group type: EXPERIMENTAL
Intervention: HMD functioning without additional aids (Group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: HMD switched off (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional working aids (Group 1)
Number of subjects: 45
Study: 15897212

Group type: EXPERIMENTAL
Intervention: Disclosure of screening questionnaire (SQ) results to GPs
Number of subjects: 1785
Study: 12833999

Group type: EXPERIMENTAL
Intervention: Crataegus extract (3 times 30 drops for 8 weeks)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Crataegus extract
Number of subjects: 143
Study: 11764109

Group type: COMPARATOR
Intervention: Group O: Prodigy resin‐based composite with OptiBond FL according to manufacturer's instructions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group A: Prolonged etching (60 s)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group B: No etching of dentin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group C: Excessive drying after etching
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group D: Short rewetting after excessive drying
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group E: Air drying and rewetting
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group F: Blot drying
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group G: Saliva contamination
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group H: Application of primer and immediate drying
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group I: Application of only primer
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group J: Application of only adhesive
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group K: No light curing of the adhesive before application of composite
Number of subjects: 96
Study: 8857633

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study: 1284157

Group type: EXPERIMENTAL
Intervention: Gallopamil (50 micrograms/kg over 5 min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (i.v. 10-ml bolus)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atenolol (5 mg over 5 min)
Number of subjects: 42
Study: 2857523

Group type: EXPERIMENTAL
Intervention: Beta-blockade therapy (BB) with metoprolol, titrated from 12.5 to 50 mg twice daily, final average dose 61 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (C) alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Beta-blockade therapy (BB)
Number of subjects: 50
Study: 31427046

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (675 mg month 1; placebo months 2 and 3)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (225 mg in episodic migraine and 675 mg in chronic migraine month 1; 225 mg months 2 and 3)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study: 28415897

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23766285

Group type: EXPERIMENTAL
Intervention: 0.12% CHX with an ADS (T2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.12% CHX without an ADS (T1)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 26
Study: 22958799

Group type: EXPERIMENTAL
Intervention: Usual care plus access to the online BREATH intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study: 19651711

Group type: EXPERIMENTAL
Intervention: 6-month quality improvement intervention
Number of subjects: 418

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 418
Study: 17908184

Group type: EXPERIMENTAL
Intervention: Lotion treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reviscometer measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual assessment for dryness and redness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corneometer, Cutometer, Reviscometer, Evaporimeter and squamometry
Number of subjects: 0
Study: 14732734

Group type: EXPERIMENTAL
Intervention: Repeated oral melatonin (2.5 mg) intake 1 hour before sleep for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single dose of melatonin (2.5 mg)
Number of subjects: 16
Study: 11843031

Group type: EXPERIMENTAL
Intervention: Balanced 2.8 MJ meal (23% fat)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Balanced low calorie 1.6 MJ meal (25% fat)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High fat 2.8 MJ meal (58% fat)
Number of subjects: 13
Study: 9500750

Group type: EXPERIMENTAL
Intervention: Enzyme-containing bar product
Number of subjects: 61
Study: 7852749

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg per day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg per day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg retard twice a day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (4 weeks prior to treatment)
Number of subjects: 72